The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
High blood pressure and cardiovascular disease
Fuchs, F. D., & Whelton, P. K. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14240 · Cited by 1,948
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Kelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 874
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Self-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Behavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 605
Cardiovascular consequences of metabolic syndrome
Tune, J. D., Goodwill, A. G., Sassoon, D., & Mather, K. J. (2017) · Translational research · doi:10.1016/j.trsl.2017.01.001 · Cited by 645
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 547
A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice
Wadden, T. A., Volger, S., Sarwer, D. B., Vetter, M. L., Tsai, A. G., Berkowitz, R. I., Kumanyika, S., Schmitz, K. H., Diewald, L. K., Barg, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109220 · Cited by 487
Drugs That May Cause or Exacerbate Heart Failure
Page, R. L., II, O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. M. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 495
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 431
Kim, H.-S., Lee, S., & Kim, J. H. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e213 · Cited by 370
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 490
Key Concepts of Clinical Trials: A Narrative Review
Umscheid, C. A., Margolis, D. J., & Grossman, C. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2475 · Cited by 414
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 411
Cardiovascular risk and obesity
Cercato, C., & Fonseca, F. A. H. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0468-0 · Cited by 426
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Ng, A. C. T., Delgado, V., Borlaug, B. A., & Bax, J. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00465-5 · Cited by 350
Obesity and weight management in the elderly
Han, T. S., Tajar, A., & Lean, M. E. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr002 · Cited by 327
Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
Kramer, C. K., Leitão, C. B., Pinto, L. C. F., Canani, L. H. S., de Azevedo, M. J., & Gross, J. L. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00846.x · Cited by 323
Comprehensive review of cardiovascular toxicity of drugs and related agents
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remião, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21476 · Cited by 335
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Hoelscher, D. M., Kirk, S., Ritchie, L. D., & Cunningham-Sabo, L. D. (2013) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2013.08.004 · Cited by 321
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293
“In 2010 thiswas the reason for theUS Food andDrug Administration (FDA) requesting withdrawal of propoxyphene, an opioid pain relievermarketed by Xanodyne Pharmaceuticals [10], and of sibutramine, a weight loss agent marketed by Abbott Laboratories [11].”
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 296
WITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
RetractedAdipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Rare adipose disorders (RADs) masquerading as obesity
Herbst, K. L. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.153 · Cited by 272
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
Wu, L., Zhang, L., Li, B., Jiang, H., Duan, Y., Xie, Z., Shuai, L., Li, J., & Li, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00122 · Cited by 255
Tucker, J., Fischer, T., Upjohn, L., Mazzera, D., & Kumar, M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3337 · Cited by 251
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides‐Demos, L. L., Piccenna, L. G., & McNeil, J. J. (2010) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 241
Convertible visceral fat as a therapeutic target to curb obesity
Giordano, A., Frontini, A., & Cinti, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.31 · Cited by 241
Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis
Berglund, E. D., Liu, C., Sohn, J., Liu, T., Kim, M. H., Lee, C. E., Vianna, C. R., Williams, K. W., Xu, Y., & Elmquist, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70338 · Cited by 232
Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
Kalil, G. Z., & Haynes, W. G. (2011) · Hypertension Research · doi:10.1038/hr.2011.173 · Cited by 234
Moreno, B., Bellido, D., Sajoux, I., Goday, A., Saavedra, D., Crujeiras, A. B., & Casanueva, F. F. (2014) · Endocrine · doi:10.1007/s12020-014-0192-3 · Cited by 222
Hoyos, C. M., Killick, R., Yee, B. J., Phillips, C. L., Grunstein, R. R., & Liu, P. Y. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201420 · Cited by 204
Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., & Uchida, H. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu030 · Cited by 210
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Verpeut, J. L., & Bello, N. T. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.909405 · Cited by 202
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Brown Adipose Tissue—A Translational Perspective
Carpentier, A. C., Blondin, D. P., Haman, F., & Richard, D. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac015 · Cited by 218
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S., & Bloom, S. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 204
Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Gaal, L. F. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 193
Leiter, L. A., FITCHETT, D. H., Gilbert, R. E., Gupta, M., Mancini, G. B. J., McFarlane, P. A., Ross, R., Teoh, H., Verma, S., Anand, S. S., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.054 · Cited by 195
Self-citationAnti-obesity drugs: a review about their effects and their safety
Derosa, G., & Maffioli, P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.675326 · Cited by 188
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.055 · Cited by 213
Dedov, I. I., Mel'nichenko, G. A., Shestakova, M. V., Troshina, E. A., Mazurina, N. V., Shestakova, E. A., Yashkov, Y. I., Неймарк, А. Е., Biryukova, E. V., Bondarenko, I. Z., et al. (2018) · Obesity and metabolism · doi:10.14341/omet2018153-70 · Cited by 209
FDA-Approved Anti-Obesity Drugs in the United States
Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.009 · Cited by 175
Laparoscopic Sleeve Gastrectomy in 108 Obese Children and Adolescents Aged 5 to 21 Years
Alqahtani, A. R., Antonisamy, B., Alamri, H., Elahmedi, M. O., & Zimmerman, V. A. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318251e92b · Cited by 172
The role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R., Tan, T., & Bewick, G. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 180
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
Saad, F., Haider, A., Doros, G. D., & Traish, A. M. (2013) · Obesity · doi:10.1002/oby.20407 · Cited by 161
New Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 160
Ghosh-Swaby, O. R., Goodman, S. G., Leiter, L. A., Cheng, A., Connelly, K. A., Fitchett, D., Jüni, P., Farkouh, M. E., & Udell, J. A. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30038-3 · Cited by 159
Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 163
Drug interventions for the treatment of obesity in children and adolescents
Axon, E., Atkinson, G., Richter, B., Metzendorf, M., Baur, L. A., Finer, N., Corpeleijn, E., O’Malley, C. L., & Ells, L. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012436 · Cited by 164
Self-citationSIRT1 Deacetylase in SF1 Neurons Protects against Metabolic Imbalance
Ramadori, G., Fujikawa, T., Anderson, J. G., Berglund, E. D., Frazão, R., Michán, S., Vianna, C. R., Sinclair, D. A., Elias, C. F., & Coppari, R. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.014 · Cited by 158
Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase: A Review
Seyedan, A., Alshawsh, M. A., Alshagga, M. A., Koosha, S., & Mohamed, Z. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/973143 · Cited by 161
Jordan, J., Yumuk, V., Schlaich, M. P., Nilsson, P. M., Zahorska‐Markiewicz, B., Grassi, G. M., Schmieder, R. E., Engeli, S., & Finer, N. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283537347 · Cited by 156
Self-citationCentrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Saad, F., Aversa, A., M. Isidori, A., & J. Gooren, L. (2012) · Current Diabetes Reviews · doi:10.2174/157339912799424573 · Cited by 148
Caterson, I. D., Finer, N., Coutinho, W. F., Gaal, L. F. V., Maggioni, A. P., Torp-Pedersen, C. T., Sharma, A. M., Legler, U. F., Shepherd, G., Rode, R. A., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01554.x · Cited by 150
Self-citationKloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 173
Adipokines at the crossroad between obesity and cardiovascular disease
Morel, S., Kwak, B. R., Rohner‐Jeanrenaud, F., Steffens, S., & Molica, F. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0513 · Cited by 149
Toward a broader view of mechanisms of drug cardiotoxicity
Mamoshina, P., Rodríguez, B., & Bueno‐Orovio, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100216 · Cited by 153
Kelly, A. S., Metzig, A. M., Rudser, K. D., Fitch, A., Fox, C. K., Nathan, B. M., Deering, M. M., Schwartz, B. L., Abuzzahab, M. J., Gandrud, L. M., et al. (2011) · Obesity · doi:10.1038/oby.2011.337 · Cited by 143
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
Ablation of LGR4 promotes energy expenditure by driving white-to-brown fat switch
Wang, J., Liu, R., Wang, F., Hong, J., Li, X., Chen, M., Ke, Y., Zhang, X., Ma, Q., Wang, R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2867 · Cited by 142
Pack, Q. R., Rodríguez-Escudero, J. P., Thomas, R. J., Ades, P. A., West, C. P., Somers, V. K., & López-Jiménez, F. A. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.033 · Cited by 133
Toxicity of Weight Loss Agents
Yen, M., & Ewald, M. B. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0213-7 · Cited by 132
Obesity and cardiovascular risk
Kotsis, V., Jordan, J., Micić, D., Finer, N., Leitner, D. R., Toplak, H., Tokgözoğlu, L. S., Athyros, V. G., Elisaf, M., Filippatos, T. D., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001730 · Cited by 141
Self-citationNovel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 141
Clinical psychopharmacology of eating disorders: a research update
Hay, P., & Claudino, A. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000460 · Cited by 133
The future role of gut hormones in the treatment of obesity
Troke, R., Tan, T., & Bloom, S. R. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 128
Principles of Conservative Prescribing
Schiff, G. D. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.256 · Cited by 125
Long-term effects of weight-reducing diets in hypertensive patients
Siebenhofer, A., Jeitler, K., Berghold, A., Waltering, A., Hemkens, L. G., Semlitsch, T., Pachler, C., Strametz, R., & Horvath, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008274.pub2 · Cited by 121
Rise and fall of anti-obesity drugs
Li, M. (2011) · World Journal of Diabetes · doi:10.4239/wjd.v2.i2.19 · Cited by 117
Safety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 119
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
“Several anti-obesity medications have been linked to increased blood pressure, heart rate and cardiovascular risk, leading to marketing authorization withdrawal.(4) Regulatory authorities now require all new obesity and T2DM medications to demonstrate no excess cardiovascular health risks.”
BackgroundSelf-citationPharmacotherapy for the management of obesity
Patel, D. K. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.001 · Cited by 120
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 118
Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity · doi:10.1002/oby.23621 · Cited by 113
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Strategies to Treat Obesity in Patients With CKD
Chintam, K., & Chang, A. R. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.016 · Cited by 113
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
